3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
10
Breast
4
Gastrointestinal
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
Conditions
Sarcoma
22
Melanoma
6
Histiocytoma, Malignant Fibrous
6
Gastrointestinal Stromal Tumors
5
Osteosarcoma
4
Neoplasm Metastasis
4
Gliosarcoma
4
Neuroblastoma
3
Hemangiosarcoma
3
Chordoma
3
Bone Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
pembrolizumab
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
Fluorouracil
4
Filgrastim
4
Cetuximab
3
fludarabine
2
cemiplimab
2
belinostat
2
atezolizumab
2
Temozolomide
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Nivolumab
2
Ipilimumab
2
Cyclophosphamide
2
Bortezomib
2
AH 111585
2
zanidatamab
1
vocimagene amiretrorepvec
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
repotrectinib
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Ipilimumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled